As the pharmaceutical landscape shifts toward increasingly complex therapies and innovative delivery platforms, the global CDMO market continues to grow at a remarkable pace. According to BCC Research, the CDMO sector is expected to surpass $190 billion by 2029, driven largely by the rising demand for advanced formulations, including liposomes, nanoparticles, and nucleic acid-based therapeutics.
In this dynamic environment, Litchlab stands out as a dedicated CDMO specializing in liposomal drug delivery systems, offering end-to-end services from early-stage formulation design to GMP-compliant clinical batch production. Our mission is to enable pharmaceutical companies worldwide to accelerate their drug development pipelines with robust, scalable, and regulatory-ready liposomal solutions.
Technical Excellence, End-to-End Support
Litchlab integrates state-of-the-art technologies to ensure seamless translation from laboratory research to industrial-scale manufacturing:
✅ Liposome Production: thin-film hydration, ethanol injection, microfluidics — optimized for efficiency and stability;
✅ Nucleic Acid Formulations: cationic and ionizable lipid systems designed for superior encapsulation and transfection;
✅ Lyophilization Development: cryoprotectant screening and cycle optimization for long-term stability and global distribution readiness;
✅ Process Scale-Up: smooth tech transfer from R&D scale to GMP production with rigorous process validation;
✅ Analytical Characterization: DLS, zeta potential, encapsulation efficiency, leakage, morphology (Cryo-TEM, AFM), ICH-compliant stability testing;
✅ Regulatory Support: IND, NDA, and ANDA submissions for FDA, EMA, and NMPA.
💡 Liposomes — A Cornerstone in Modern Drug Delivery
Liposomes are phospholipid-based nanoscale vesicles designed to encapsulate a wide range of APIs, providing enhanced bioavailability, targeted delivery, and controlled release profiles. They are particularly valuable in overcoming challenges such as poor solubility, rapid metabolism, and off-target toxicity.
At Litchlab, we offer comprehensive liposome development services tailored to various therapeutic applications:
| Liposome Type | Application Focus |
|---|---|
| Conventional Liposomes | Small molecules / Peptides |
| PEGylated (Stealth) Liposomes | Extended circulation time, immune evasion |
| Cationic Liposomes | siRNA / mRNA / DNA delivery |
| pH-Sensitive Liposomes | Tumor microenvironments, inflammation targeting |
| Thermo-Sensitive Liposomes | Localized temperature-triggered release |
| Immunoliposomes | Active targeting via antibodies/ligands |
🏆 Why Litchlab?
As the biopharmaceutical industry embraces the era of precision delivery systems, Litchlab’s advanced liposomal technology platform provides a reliable, flexible, and GMP-compliant foundation to accelerate your drug development journey.
From small molecule APIs to nucleic acid therapeutics and complex biologics, Litchlab is committed to helping you transform innovation into clinical success.
📞 Discover more:
👉 Visit: www.litchlab.com
📧 Contact: Sales@litchlab.com
